DETIMEDAC 500mg powder infusion solution medication leaflet

L01AX04 dacarbazine • Antineoplastic and immunomodulating agents | Alkylating agents | Other alkylating agents

Dacarbazine is a chemotherapy medication used for the treatment of malignant melanoma, Hodgkin's disease, and other types of cancer. It acts as an alkylating agent, interfering with DNA synthesis and inhibiting cell division.

The medication is administered via intravenous infusion, with the dose determined by the physician based on the type of cancer and the patient's overall condition. Common side effects include nausea, vomiting, fatigue, and bone marrow suppression.

Dacarbazine is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with hepatic or renal impairment.

This medication is an important option in cancer treatment, helping to reduce tumor size and improve the prognosis of affected patients.

General data about DETIMEDAC 500mg

Substance: dacarbazine

Date of last drug list: 01-06-2025

Commercial code: W69114001

Concentration: 500mg

Pharmaceutical form: powder infusion solution

Quantity: 1

Product type: generic

Price: 522.82 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: ONCOTEC PHARMA PRODUTION GMBH - GERMANIA

Holder: TRIDENT PHARMA SRL - ROMANIA

Number: 743/2022/01

Concentrations available for dacarbazine

1000mg, 100mg, 200mg, 500mg

Other substances similar to dacarbazine

Compensation lists for DETIMEDAC 500mg TRIDENT

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

522.82 RON

522.82 RON

0.00 RON